



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/581,717

06/05/2006

Jinichiro Koga

Q95277

3601

23373 7590 04/02/2008  
SUGHRUE MION, PLLC  
2100 PENNSYLVANIA AVENUE, N.W.  
SUITE 800  
WASHINGTON, DC 20037

EXAMINER

FRONDA, CHRISTIAN L

ART UNIT

PAPER NUMBER

1652

MAIL DATE

DELIVERY MODE

04/02/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/581,717	<b>Applicant(s)</b> KOGA ET AL.	
	<b>Examiner</b> CHRISTIAN L. FRONDA	<b>Art Unit</b> 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 25 February 2008.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-28 is/are pending in the application.
- 4a) Of the above claim(s) 7-15 and 19-28 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-6 and 16-18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 05 June 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>6/06, 6/07, 2/08</u> .  | 6) <input type="checkbox"/> Other: _____                          |

### DETAILED ACTION

1. Applicant's election with traverse of Group I, claims 1-6 and 16-18, in the reply filed on 02/25/2008 is acknowledged. Applicants' arguments have been fully considered but are not persuasive. Because the claims recite "derived from", instead of "isolated" or "obtained", then the claims are deemed to encompass any endoglucanase irrespective of its amino acid sequence and structure, and is not limited to any endoglucanase isolated from any microorganism belonging to the genus *Staphylotrichum*.

Thus, the same or corresponding technical feature shared among Inventions 1-3 is a protein having endoglucanase activity. However, the reference of Rasmussen et al. (WO 91/17243, published 11/14/1991; PTO 1449 from IDS filed 06/05/2006) teaches such protein having endoglucanase activity as previously stated. Therefore, the same or corresponding technical feature is not special since it was known in the prior art and therefore cannot make a contribution over the prior art. Since the inventions lack the same or corresponding special technical feature, then the inventions are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-6 and 16-18 are under consideration in this Office Action.

3. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

4. The information disclosure statements (IDS) submitted on 06/05/2007, 06/21/2007, and 02/25/2008 have been considered, and a signed copy of form PTO-1449 for each IDS is enclosed with the instant Office Action.

5. Claim 16 is objected to for depending from nonelected claim 15. Applicant is required to cancel the claim, or amend the claim to place the claim in proper dependent form, or rewrite the claim in independent form.

***Claim Rejections - 35 U.S.C. § 101***

6. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

7. Claims 1-6 are rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter.

Claims 1-6, as written, do not sufficiently distinguish over proteins as they exist naturally because the claim does not particularly point out any non-naturally occurring differences between the claimed product and the naturally proteins. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of "An isolated protein". See MPEP 2105.

***Claim Rejections - 35 U.S.C. § 112, First Paragraph***

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claim 6 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated protein comprising the amino acid sequence of SEQ ID NO: 3 and

Art Unit: 1652

having endoglucanase activity; does not reasonably provide enablement for any modified protein having endoglucanase activity and comprising an amino acid sequence in which 1-30 amino acids are deleted, substituted, inserted or added to SEQ ID NO: 3, and any homologous protein having endoglucanase activity and comprising an amino acid sequence having at least 85% homology to SEQ ID NO: 3. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

According to MPEP 2164.01(a), factors considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue” include, but are not limited to: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

MPEP § 2164.04 states that while the analysis and conclusion of a lack of enablement are based on the factors discussed in MPEP § 2164.01(a) and the evidence as a whole, it is not necessary to discuss each factor in the written enablement rejection. The language should focus on those factors, reasons, and evidence that lead the examiner to conclude that the specification fails to teach how to make and use the claimed invention without undue experimentation, or that the scope of any enablement provided to one skilled in the art is not commensurate with the scope of protection sought by the claims. Accordingly, the factors most relevant to the instant rejection are addressed in detail below.

The breadth of the claims: The claim encompasses any modified protein having endoglucanase activity and comprising an amino acid sequence in which 1-30 amino acids are deleted, substituted, inserted or added to SEQ ID NO: 3, and any homologous protein having endoglucanase activity and comprising an amino acid sequence having at least 85% homology to SEQ ID NO: 3.

The state of the prior art; The relative skill of those in the art; and The predictability or unpredictability of the art: It is well known in the prior art that the amino acid sequence of a

protein determines the protein's structural and functional properties. Predictability of which changes can be tolerated in a protein's amino acid sequence to obtain a desired endoglucanase activity requires knowledge and guidance regarding specific amino acid residue(s) in the protein's amino acid sequence, if any, are tolerant of modification and which are conserved (i.e., expectedly intolerant to modification) and detailed knowledge of the protein's structure, and the ways in which the protein's structure relates to its function. The reference of Chica et al. (Curr Opin Biotechnol. 2005 Aug;16(4):378-84; PTO 892) teaches that the complexity of the structure/function relationship in enzymes has proven to be the factor limiting the general application of rational enzyme modification and design, where rational enzyme modification and design requires in-depth understanding of structure/function relationships.

The positions within a protein's amino acid sequence where modifications can be made with a reasonable expectation of success in obtaining a polypeptide having the desired endoglucanase activity are limited in any protein and the result of such modifications is highly unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g., multiple substitutions, deletions, additions, and combinations thereof.

Methods for isolating or generating variants and mutants using random mutagenesis techniques were known in the art. However, neither the specification nor the state of the art at the time of the invention provided the necessary guidance for altering the amino acid sequence of SEQ ID NO: 3 with an expectation of obtaining a polypeptide having the same endoglucanase activity. At the time of the invention, there was a high level of unpredictability associated with altering a polypeptide sequence with an expectation that the polypeptide will maintain the same desired biological activity. For example, the reference of Witkowski et al. (Biochemistry. 1999 Sep 7; 38(36): 11643-50; PTO 892) teaches that only a single amino acid substitution results in conversion of the activity of a polypeptide to a second, distinct activity (see e.g., Table 1, page 11647). In addition, the reference of Seffernick et al. (J Bacteriol. 2001 Apr; 183 (8): 2405-10; PTO 892) teaches that two proteins with 98% amino acid sequence identity were found to catalyze different reactions, where one protein has melamine deaminase activity and the other protein has atrazine chlorohydrolase activity (see Fig.3, page 2408; **DISCUSSION** section on page 2409).

The amount of direction provided by the inventor; and The existence of working examples: The specification discloses an endoglucanase isolated from *staphylotrichum coccosporum* comprising the amino acid sequence of SEQ ID NO: 3. However, the specification fails to disclose any specific guidance for altering the polypeptide of SEQ ID NO: 3 with the expectation that the polypeptide will still have the same endoglucanase activity, because guidance and working examples teaching unalterable structural and catalytic amino acid residues and amino acid residues tolerable to change is not provided by the specification.

The quantity of experimentation needed to make or use the invention based on the content of the disclosure: While methods of isolating and/or generating variants of a polypeptide were known in the art at the time of the invention and the specification provides general teachings for searching and screening for the claimed invention, it was not routine in the art to screen by a trial and error process for all polypeptides having a substantial number of modifications as encompassed by the claim(s) for those that maintain the same desired endoglucanase activity. General teachings from the specification regarding screening and searching for the claimed invention using enzyme assays is not specific guidance for making and using the claimed invention.

Therefore, in view of the overly broad scope of the claims, the specification's lack of specific guidance and additional working examples, the high level of unpredictability as evidenced by the prior art, and the amount of experimentation required, it would require undue experimentation for a skilled artisan to make and use the entire scope of the claimed invention.

Applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* (858 F.2d 731, 8 USPQ 2nd 1400 (Fed. Cir. 1988)).

10. Claims 1, 5, and 16-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which

was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

According to MPEP 2163, to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., *Moba, B.V. v. Diamond Automation, Inc.*, 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed.Cir. 2003); *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d at 1563, 19 USPQ2d at 1116.

Because claims 1 and 5 recite “derived from”, instead of “isolated” or “obtained”, then the claim is deemed to encompass any endoglucanase irrespective of its amino acid sequence and structure, and is not limited to any endoglucanase isolated from any microorganism belonging to the genus *Staphylotrichum*. Thus, the claims are genus claims drawn to a genus of proteins having endoglucanase activity from any biological source comprising any amino acid sequence and structure. The scope of this genus includes many members with widely differing structural, chemical, and physiochemical properties such as widely differing amino acid sequences and biological functions. Furthermore, the genus is highly variable because a significant number of structural and biological differences between genus members exist.

For claims drawn to a genus, MPEP § 2163 states the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show that applicant was in possession of the claimed genus. See *Eli Lilly*, 119 F.3d at 1568, 43 USPQ2d at 1406.

The instant specification discloses an endoglucanase isolated from *staphylotrichum coccosporum* comprising the amino acid sequence of SEQ ID NO: 3. However, the instant specification does not describe and define any structural features, amino acid sequences, and/or biological functions that are commonly possessed by members of the claimed genus. The



specification fails to disclose a representative number of species of the claimed genus, which includes many members with widely differing structural, chemical, and biological functions.

MPEP § 2163 states that a representative number of species means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. In this case, the endoglucanase isolated from *staphylotrichum coccosporum* comprising the amino acid sequence of SEQ ID NO: 3 is insufficient to be representative of the attributes and features common to all the members of the claimed genus. Thus, one skilled in the art cannot visualize or recognize the identity of members of the claimed genus.

*Vas-Cath, Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116). One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class, where the specification provided only the bovine sequence.

In view of the above considerations, one of skill in the art would not recognize that applicants were in possession of a genus of proteins having endoglucanase activity from any biological source comprising any amino acid sequence and structure. Dependent claims 5 and 16-18 are also rejected because they do not correct the defect of claim 1. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. § 112, first paragraph, is severable from its enablement provision (see page 115).

***Claim Rejections - 35 USC § 102***

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

12. Claims 1, 5, and 16-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasmussen et al. (WO 91/17243, published 11/14/1991; PTO 1449 from IDS filed 06/05/2006).

Rasmussen et al. teach a protein having endoglucanase activity which is produced by a recombinant process in host cells, a cellulase preparation comprising said endoglucanase, and detergent composition comprising said endoglucanase (see entire publication, especially pages 4-12, pages 14-46, and claims 1-9 and 16-26). Because claims 1 and 5 recite “derived from”, instead of “isolated” or “obtained”, then the claim is deemed to encompass any endoglucanase irrespective of its amino acid sequence and structure, and is not limited to any endoglucanase isolated from any microorganism belonging to the genus *Staphylotrichum*. Furthermore, regarding claim 16 no patentable weight is given to the process for making the endoglucanase since there are no structural difference between the produced protein of claim 16 and the reference protein taught by Rasmussen et al. Thus, the reference teachings anticipate the claimed invention.

***Conclusion***

13. No claim is allowed.

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Thursday and alternate Fridays between 9:00AM - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the

Art Unit: 1652

examiner's supervisor, Nashaat Nashed can be reached on (571)272-0934. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

15. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CLF

/Tekchand Saidha/

Primary Examiner, Art Unit 1652